Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specific weight loss in hyperthyroidism

P Bratusch-Marrain, P Schmid, W Waldhäusl

    Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
    |September 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

    ESMO open·2026
    Same author

    Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025

    Hyperthyroidism significantly increases specific weight loss (SWL), a measure of metabolic rate. SWL normalization during treatment lags behind thyroid hormone level decreases, suggesting SWL is a more sensitive indicator of metabolic state.

    Area of Science:

    • Endocrinology
    • Metabolic Medicine

    Background:

    • Hyperthyroidism is characterized by an elevated metabolic rate.
    • Assessing metabolic turnover accurately is crucial for managing hyperthyroid patients.

    Purpose of the Study:

    • To evaluate specific weight loss (SWL) as a marker of metabolic turnover in hyperthyroid patients.
    • To compare SWL with serum thyroid hormone levels (T4 and T3) during treatment.

    Main Methods:

    • Utilized a novel buoyancy scale with high precision (10 mg susceptibility) to measure SWL (mg.kg-1.min-1).
    • Compared SWL in hyperthyroid patients (n=22) and healthy controls (n=11).
    • Monitored SWL and thyroid hormone levels during antithyroid treatment.

    Main Results:

    Related Experiment Videos

  • Hyperthyroid patients exhibited significantly higher SWL (22.0 +/-1.4 mg.kg-1.min-1) than controls (10.0 +/-0.4 mg.kg-1.min-1).
  • SWL decreased with treatment, paralleling initial hormone level drops but normalizing slower than hormone levels.
  • No significant correlation was found between thyroid hormone levels and SWL before or during treatment.

    • Conclusions:

    • Specific weight loss (SWL) provides a more comprehensive assessment of metabolic rate in hyperthyroidism than serum T4 and T3 levels alone.
    • Metabolic rate normalization, as indicated by SWL, is a slower process than the reduction of circulating thyroid hormones.